<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04870866</url>
  </required_header>
  <id_info>
    <org_study_id>2017/419</org_study_id>
    <nct_id>NCT04870866</nct_id>
  </id_info>
  <brief_title>NAD Supplementation to Prevent Progressive Neurological Disease in Ataxia Telangiectasia</brief_title>
  <official_title>NAD Supplementation to Prevent Progressive Neurological Disease in Ataxia Telangiectasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Akershus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Bergesen Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>South-Eastern Norway Regional Health Authority</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sykehuset Innlandet HF</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St. Olavs Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Haukeland University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital of North Norway</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Bergen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Akershus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study investigates the effect of dietary supplementation of nicotinamide ribonucleoside&#xD;
      (NR) in children with ataxia telangiectasia (AT), with main focus on neurological symptoms.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ataxia Telangiectasia (AT) is a genetic disease, where patients are born with mutations in&#xD;
      the Ataxia- Telangiectasia Mutated (ATM) gene. The gene codes for the ATM kinase, which is&#xD;
      required for repair of DNA double-stranded breaks and DNA damage response signalling.&#xD;
&#xD;
      There is no treatment available for the neurological manifestations of AT.&#xD;
&#xD;
      The study investigates the effects of NR (300 mg/day) during 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 5, 2019</start_date>
  <completion_date type="Anticipated">February 16, 2027</completion_date>
  <primary_completion_date type="Anticipated">February 3, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Open label proof of concept</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>NAD metabolome</measure>
    <time_frame>2 years</time_frame>
    <description>Increase of NAD+ and other stable NAD+ metabolites (referred to as the NAD metabolome) in blood</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient well being</measure>
    <time_frame>2 years</time_frame>
    <description>Improved or stabilized health-related quality of life (HRQOL) measured with the Pediatric Quality of Life Inventory (PedSQL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Motoric function - The Scale for the Assessment and Rating of Ataxia (SARA)</measure>
    <time_frame>2 years</time_frame>
    <description>Stabilized motoric function measured with SARA.&#xD;
The SARA scale is made up of measurements related to gait, stance, sitting, speech, finger-chase test, nose-finger test, fast alternating movements and heel-shin test.&#xD;
The range is from no ataxia (value 0) to severe ataxia (value 40).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Motoric function - The International Cooperative Ataxia Rating Scale (ICARS)</measure>
    <time_frame>2 years</time_frame>
    <description>Stabilized motoric function measured with ICARS.&#xD;
The ICARS scale is made from measurements of postural and gait disturbances, limb ataxia, dysarthria, and oculomotor disorders.&#xD;
The range is from no ataxia (value 0) to severe ataxia (value 100).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Motoric function - Customized gait scale (GS)</measure>
    <time_frame>2 years</time_frame>
    <description>Stabilized motoric function measured with GS.&#xD;
The gait scale assess gait functionality in patients with Ataxia-telangiectasia.&#xD;
The range is from no walking ability (value 0) to normal walking ability according to age and maturity (value 10).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Motoric function - AT Neuro Examination Scale Toolkit, updated version (AT-NEST)</measure>
    <time_frame>2 years</time_frame>
    <description>Stabilized motoric function measured with AT-NEST.&#xD;
The AT-NEST scale is made from scoring of speech, handwriting/drawing, oculomotor, ataxia, muscle strength, neuropathy, growth, nutrition, learning ability/cognition, MS mental state.&#xD;
The range is from normal (value 144) to severe ataxia (value 0).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Motoric function - Clinical Global Scale rating instrument for A-T</measure>
    <time_frame>2 years</time_frame>
    <description>Stabilized motoric function measured with Clinical Global Scale rating instrument for A-T.&#xD;
The Clinical Global Scale rating instrument for A-T scale is made from scoring of gait ataxia, dysmetria, dysarthria, extrapyramidal movements and eye movements.&#xD;
The range is from normal (value 0) to severe (value 4).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver function</measure>
    <time_frame>2 years</time_frame>
    <description>Normalized or stabilized liver function as assessed by blood levels of&#xD;
-alfa fetoprotein (AFP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood sugar control</measure>
    <time_frame>2 years</time_frame>
    <description>Normalized or stabilized blood sugar levels as measured in blood:&#xD;
-HbA1c</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mitochondrial function</measure>
    <time_frame>2 years</time_frame>
    <description>Normalized or stabilized mitochondrial markers in blood:&#xD;
lactate&#xD;
lactate dehydrogenase&#xD;
FGF21</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Ataxia Telangiectasia</condition>
  <arm_group>
    <arm_group_label>NR treated</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nicotinamide ribonuceloside (NR), sold under the trade name Niagen™</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicotinamide ribonucleoside</intervention_name>
    <description>Two year intervention</description>
    <arm_group_label>NR treated</arm_group_label>
    <other_name>Niagen</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  clinically and molecular verified classical A-T disease&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  less than 2 years of age&#xD;
&#xD;
          -  participation in other on-going study&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  liver failure&#xD;
&#xD;
          -  other severe medical conditions considered to set patient at risk&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hilde L Nilsen</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Akershus</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hilde Loge Nilsen</name>
      <address>
        <city>Lørenskog</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <reference>
    <citation>Fang EF, Kassahun H, Croteau DL, Scheibye-Knudsen M, Marosi K, Lu H, Shamanna RA, Kalyanasundaram S, Bollineni RC, Wilson MA, Iser WB, Wollman BN, Morevati M, Li J, Kerr JS, Lu Q, Waltz TB, Tian J, Sinclair DA, Mattson MP, Nilsen H, Bohr VA. NAD(+) Replenishment Improves Lifespan and Healthspan in Ataxia Telangiectasia Models via Mitophagy and DNA Repair. Cell Metab. 2016 Oct 11;24(4):566-581. doi: 10.1016/j.cmet.2016.09.004.</citation>
    <PMID>27732836</PMID>
  </reference>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>April 23, 2021</study_first_submitted>
  <study_first_submitted_qc>April 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 4, 2021</study_first_posted>
  <last_update_submitted>May 5, 2021</last_update_submitted>
  <last_update_submitted_qc>May 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Akershus</investigator_affiliation>
    <investigator_full_name>Hilde Nilsen</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>ataxia telangiectasia</keyword>
  <keyword>nicotinamide ribonucleoside</keyword>
  <keyword>Louis-Bar syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ataxia</mesh_term>
    <mesh_term>Cerebellar Ataxia</mesh_term>
    <mesh_term>Nervous System Diseases</mesh_term>
    <mesh_term>Ataxia Telangiectasia</mesh_term>
    <mesh_term>Telangiectasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Niacinamide</mesh_term>
    <mesh_term>Niacin</mesh_term>
    <mesh_term>Nicotinic Acids</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

